

# An optical coherence tomography study to determine stent coverage in polymer coated versus bare metal rapamycin eluting stents

<b>Submission date</b> 16/06/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 25/06/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 02/12/2010	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Miles Dalby

### Contact details

Harefield Hospital  
Hill End Road  
Harefield  
United Kingdom  
UB9 6JH  
+44 (0)1895828990  
m.dalby@rbht.nhs.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

# Study information

## Scientific Title

### Study objectives

The hypothesis of this study is that there is more complete stent strut coverage in the polymer free rapamycin eluting 'Yukon' stent (Translumina), compared with the durable polymer based rapamycin eluting stent 'Cypher' (Cordis) using optical coherence tomography at 3 months post implantation.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approval from UK Central Office of Research Ethics Committees (COREC) on 4th October 2006 (ref: 06/Q0404/61)

### Study design

Single-centre two-arm randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Not Specified

## Participant information sheet

### Health condition(s) or problem(s) studied

Coronary artery disease

### Interventions

In brief all patients will be undergoing drug eluting intracoronary stent deployment as clinically indicated. Patients will be randomly allocated to receive a Yukon (rapamycin eluting polymer free) or Cypher (rapamycin eluting polymer coated) stent using standard clinical protocols according to the discretion of the implanting cardiologist. Patients will be systematically re-catheterised at 90 days and undergo optical coherence tomography.

### Intervention Type

Other

### Phase

Not Specified

**Primary outcome measure**

Comparison of binary stent strut coverage between the Yukon (rapamicin eluting polymer free) and Cypher (rapamicin eluting polymer coated) groups at 90 day optical coherence tomography.

**Secondary outcome measures**

Comparison of mean neointimal thickness between the Yukon (rapamicin eluting polymer free) and Cypher (rapamicin eluting polymer coated) groups at 90 day optical coherence tomography.

**Overall study start date**

20/10/2006

**Completion date**

01/08/2007

## Eligibility

**Key inclusion criteria**

1. Age 18-75
2. Stable or unstable angina, Non-ST Elevation Myocardial Infarction (NSTEMI) but not ST-Elevation Myocardial Infarction (STEMI; primary Percutaneous Coronary Intervention (PCI) or rescue angioplasty) who have been pain-free for > 24h
3. Single or multiple lesions in a native coronary artery
4. 50-99% diameter stenosis
5. Lesion length 8-28mm (visually estimated)
6. Vessel diameter 2.5-3.5mm (visually estimated)

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

75 Years

**Sex**

Both

**Target number of participants**

Total 40 (20 each arm)

**Key exclusion criteria**

1. Unprotected left mainstem lesion
2. Ostial lesion
3. Bifurcation lesion requiring side branch intervention
4. Severely calcified lesion that cannot be successfully pre-dilated

5. Marked tortuosity or angulation of target vessel
6. STEMI
7. Left Ventricular (LV) ejection fraction <20%
8. Pregnancy or breast feeding
9. Coexisting comorbidity limiting life expectancy to <24 months
10. Renal impairment with Creatinine (Cr) >200 µmol/L

**Date of first enrolment**

20/10/2006

**Date of final enrolment**

01/08/2007

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Harefield Hospital**

Harefield

United Kingdom

UB9 6JH

## **Sponsor information**

**Organisation**

Royal Brompton and Harefield NHS Trust (UK)

**Sponsor details**

Hill End Road

Harefield

England

United Kingdom

UB9 6JH

+44 (0)1895828990

m.dalby@rbht.nhs.uk

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www3.rbht.nhs.uk/>

ROR

<https://ror.org/02218z997>

## Funder(s)

### Funder type

Not defined

### Funder Name

Translumina (Hechingen, Germany)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2009		Yes	No